Oculus Innovative Sciences Expands Regulatory Claims for Microcyn-Based Advanced Wound Management Products in Europe Mar 26, 2013
Oculus Innovative Sciences Announces Completion of Patient Follow-Up in Scar Management Study Mar 14, 2013
Oculus Innovative Sciences Announces Closing of Public Offering of 8,625,000 Shares of Common Stock Mar 12, 2013
Oculus Innovative Sciences, Inc. Announces Full Exercise of Underwriters' Over-Allotment Option Mar 7, 2013
Oculus Innovative Sciences Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock and Intention to Repay Certain Indebtedness Mar 7, 2013
Oculus Innovative Sciences Announces Proposed Public Offering of Common Stock and Intention to Repay Certain Indebtedness Mar 6, 2013
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Issuance of U.S. Patent for Treatment of Skin Ulcers With Microcyn(R) Technology Feb 25, 2013
Oculus Innovative Sciences Reports Revenues of $3.5 Million for the Third Quarter of Fiscal 2013 Feb 13, 2013
Ruthigen, Inc., Subsidiary of Oculus Innovative Sciences, Inc., Appoints Sameer Harish as Chief Financial Officer Feb 5, 2013
